RALLYBIO CORP (RLYB) Stock Fundamental Analysis

NASDAQ:RLYB • US75120L1008

7.54 USD
+0.74 (+10.88%)
Last: Feb 27, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall RLYB gets a fundamental rating of 3 out of 10. We evaluated RLYB against 521 industry peers in the Biotechnology industry. RLYB has a great financial health rating, but its profitability evaluates not so good. RLYB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RLYB has reported negative net income.
  • In the past year RLYB has reported a negative cash flow from operations.
  • RLYB had negative earnings in each of the past 5 years.
  • In the past 5 years RLYB always reported negative operating cash flow.
RLYB Yearly Net Income VS EBIT VS OCF VS FCFRLYB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • RLYB's Return On Assets of -20.88% is fine compared to the rest of the industry. RLYB outperforms 75.24% of its industry peers.
  • The Return On Equity of RLYB (-22.41%) is better than 81.38% of its industry peers.
Industry RankSector Rank
ROA -20.88%
ROE -22.41%
ROIC N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
RLYB Yearly ROA, ROE, ROICRLYB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RLYB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLYB Yearly Profit, Operating, Gross MarginsRLYB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • RLYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RLYB has been increased compared to 1 year ago.
  • RLYB has more shares outstanding than it did 5 years ago.
  • RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLYB Yearly Shares OutstandingRLYB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
RLYB Yearly Total Debt VS Total AssetsRLYB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • RLYB has an Altman-Z score of -2.22. This is a bad value and indicates that RLYB is not financially healthy and even has some risk of bankruptcy.
  • RLYB has a Altman-Z score (-2.22) which is comparable to the rest of the industry.
  • There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.22
ROIC/WACCN/A
WACC8.66%
RLYB Yearly LT Debt VS Equity VS FCFRLYB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • RLYB has a Current Ratio of 14.74. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
  • RLYB has a better Current ratio (14.74) than 91.55% of its industry peers.
  • RLYB has a Quick Ratio of 14.74. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 14.74, RLYB belongs to the top of the industry, outperforming 91.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.74
Quick Ratio 14.74
RLYB Yearly Current Assets VS Current LiabilitesRLYB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for RLYB have decreased strongly by -108.75% in the last year.
  • Looking at the last year, RLYB shows a quite strong growth in Revenue. The Revenue has grown by 12.71% in the last year.
EPS 1Y (TTM)-108.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-330.77%
Revenue 1Y (TTM)12.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%

3.2 Future

  • The Earnings Per Share is expected to grow by 2.36% on average over the next years.
  • Based on estimates for the next years, RLYB will show a very strong growth in Revenue. The Revenue will grow by 165.51% on average per year.
EPS Next Y71.04%
EPS Next 2Y24.25%
EPS Next 3Y18.4%
EPS Next 5Y2.36%
Revenue Next Year8.72%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%

3.3 Evolution

RLYB Yearly Revenue VS EstimatesRLYB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2029 2030 2031 200M 400M 600M 800M
RLYB Yearly EPS VS EstimatesRLYB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RLYB. In the last year negative earnings were reported.
  • Also next year RLYB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLYB Price Earnings VS Forward Price EarningsRLYB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLYB Per share dataRLYB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RLYB's earnings are expected to grow with 18.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.25%
EPS Next 3Y18.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RLYB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RALLYBIO CORP

NASDAQ:RLYB (2/27/2026, 8:00:02 PM)

7.54

+0.74 (+10.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)N/A
Inst Owners59.81%
Inst Owner Change-0.17%
Ins Owners2.36%
Ins Owner Change0%
Market Cap39.81M
Revenue(TTM)674.00K
Net Income(TTM)-14.13M
Analysts76
Price TargetN/A
Short Float %N/A
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.96%
Min EPS beat(2)11.96%
Max EPS beat(2)35.96%
EPS beat(4)4
Avg EPS beat(4)20.82%
Min EPS beat(4)11.96%
Max EPS beat(4)35.96%
EPS beat(8)7
Avg EPS beat(8)13.46%
EPS beat(12)11
Avg EPS beat(12)13.67%
EPS beat(16)12
Avg EPS beat(16)9.51%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-700%
EPS NQ rev (3m)-700%
EPS NY rev (1m)0%
EPS NY rev (3m)54.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)37.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.07
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-3.34
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-6.65
FCFYN/A
OCF(TTM)-6.65
OCFYN/A
SpS0.13
BVpS11.94
TBVpS11.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.88%
ROE -22.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.74
Quick Ratio 14.74
Altman-Z -2.22
F-Score5
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)12.47%
Cap/Depr(5y)114.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-330.77%
EPS Next Y71.04%
EPS Next 2Y24.25%
EPS Next 3Y18.4%
EPS Next 5Y2.36%
Revenue 1Y (TTM)12.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%
Revenue Next Year8.72%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%
EBIT growth 1Y45.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45%
OCF growth 3YN/A
OCF growth 5YN/A

RALLYBIO CORP / RLYB FAQ

What is the fundamental rating for RLYB stock?

ChartMill assigns a fundamental rating of 3 / 10 to RLYB.


What is the valuation status for RLYB stock?

ChartMill assigns a valuation rating of 0 / 10 to RALLYBIO CORP (RLYB). This can be considered as Overvalued.


What is the profitability of RLYB stock?

RALLYBIO CORP (RLYB) has a profitability rating of 1 / 10.